Introduction to Renal Changes

Renal function declines by approximately 1% per year beyond age 30-40, resulting in up to 40% reduction in kidney function by age 70, which necessitates careful medication management and dosage adjustments in elderly patients 1, 2

Clinical Implications

Altered pharmacokinetics and pharmacodynamics of renally excreted drugs require dosage adjustments 1, 2
Higher risk of drug toxicity, particularly with nephrotoxic agents or those with narrow therapeutic indices 1, 3

Serum creatinine alone is insufficient for evaluating renal function in the elderly due to decreased muscle mass 2
Creatinine clearance should be calculated using either the abbreviated Modification of Diet in Renal Disease (MDRD) or Cockcroft-Gault equations 3
In cases of extreme body composition or very high/low creatinine values, direct measurement methods such as 51Cr-EDTA or inulin clearance provide more accurate GFR assessment 3
Comprehensive evaluation should include urinalysis and urine albumin-to-creatinine ratio to assess for proteinuria 2

Medication dosages should be adjusted based on current GFR rather than age alone 2
Potentially nephrotoxic medications should be avoided or used with caution 2, 3
Hydration status should be carefully assessed and optimized before initiating potentially nephrotoxic therapies 1, 3
Nephrology referral should be considered when GFR falls below 45 mL/min/1.73 m² 2
When using ACE inhibitors or ARBs, an initial small decline in GFR (10-20%) can be expected and is generally acceptable 2

In patients aged ≥ 65 years, renal function declines at an average rate of ≈ 1 % per year after the third to fourth decade, leading to up to a 40 % reduction in creatinine clearance by age 70; therefore, creatinine clearance should be calculated with the Cockcroft‑Gault equation before each meropenem dosing decision. 4

Elderly patients are at high risk for acute changes in kidney function during acute illness, so creatinine clearance must be reassessed whenever the clinical status changes to ensure appropriate meropenem dose adjustments. 4